Literature DB >> 20952660

Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer.

Shaobo Yang1, Binquan Wang, Chunying Guan, Benyan Wu, Changhao Cai, Mengwei Wang, Binsheng Zhang, Tao Liu, Pingchang Yang.   

Abstract

The pathogenesis of CRC remains to be further understood. This study was designed to elucidate the role of Foxp3+IL-17+ T cells in the pathogenesis of CRC. Surgically removed CRC tissue was collected from 12 patients with CRC. The frequency and cytokine profile of Foxp3+IL-17+ T cells in CRC were examined by flow cytometry. Chemokine CXCL11 was examined in CRC tissue by Western blotting. Treg chemotaxis was examined in a transwell system. The effect of Foxp3+IL-17+ T cells on induction of cancer-initiating cells was examined; the latter's Akt and MAPK activities and colony formation were examined afterward. Abundant Foxp3+IL-17+ T cells were detected in CRC tissue that expresses high levels of TGF-β, CXCR3, CCR6, and RORγt. High levels of CXCL11 were detected in CRC tissue-derived CD68+ cells, which had a strong chemotactic effect on Foxp3+ Tregs. Hypoxia induced the expression of IL-17 in Foxp3+ Tregs; Foxp3+IL-17+ T cells were capable of inducing CRC-associated cell markers in BMMo and drove the cells to be cancer-initiating cells. High levels of phosphorylated Akt and MAPK were detected in the induced cancer-initiation cells; the latter has the capability to form a colony. CRC tissue-derived Foxp3+IL-17+ cells have the capacity to induce cancer-initiating cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952660     DOI: 10.1189/jlb.0910506

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  55 in total

Review 1.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 2.  The microbiome and colorectal neoplasia: environmental modifiers of dysbiosis.

Authors:  N D Turner; L E Ritchie; R S Bresalier; R S Chapkin
Journal:  Curr Gastroenterol Rep       Date:  2013-09

3.  Elevated proinflammatory cytokine IL-17A in the adjacent tissues along the adenoma-carcinoma sequence.

Authors:  Guanglin Cui; Hang Yang; Jianbo Zhao; Aping Yuan; Jon Florholmen
Journal:  Pathol Oncol Res       Date:  2014-05-25       Impact factor: 3.201

Review 4.  Cytokine crowdsourcing: multicellular production of TH17-associated cytokines.

Authors:  Kathleen O Busman-Sahay; Travis Walrath; Samuel Huber; William O'Connor
Journal:  J Leukoc Biol       Date:  2014-12-29       Impact factor: 4.962

Review 5.  Metabolic control of the Treg/Th17 axis.

Authors:  Joseph Barbi; Drew Pardoll; Fan Pan
Journal:  Immunol Rev       Date:  2013-03       Impact factor: 12.988

Review 6.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

Authors:  Ryuma Tokunaga; Wu Zhang; Madiha Naseem; Alberto Puccini; Martin D Berger; Shivani Soni; Michelle McSkane; Hideo Baba; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2017-11-26       Impact factor: 12.111

Review 7.  Basic principles of tumor-associated regulatory T cell biology.

Authors:  Peter A Savage; Sven Malchow; Daniel S Leventhal
Journal:  Trends Immunol       Date:  2012-09-19       Impact factor: 16.687

8.  Colon cancer stem cells: Potential target for the treatment of colorectal cancer.

Authors:  Riya Gupta; Lokesh Kumar Bhatt; Thomas P Johnston; Kedar S Prabhavalkar
Journal:  Cancer Biol Ther       Date:  2019-05-03       Impact factor: 4.742

Review 9.  The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer.

Authors:  Lequn Li; Vassiliki A Boussiotis
Journal:  Clin Immunol       Date:  2013-05-15       Impact factor: 3.969

10.  Regulatory T cells that co-express RORγt and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer.

Authors:  Stalin Chellappa; Harald Hugenschmidt; Morten Hagness; Pål D Line; Knut J Labori; Gro Wiedswang; Kjetil Taskén; Einar M Aandahl
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.